Deciphera Pharmaceuticals (DCPH) 10-K2020 FY Annual report

Filed: 9 Feb 21, 4:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Abstract, accomplishing, acid, adapt, adenocarcinoma, adherence, adult, AE, al, alanine, Alert, amino, angiogenic, AstraZeneca, atrial, Australian, Ayvakit, Bacchi, BCA, bevacizumab, BICR, boxed, bridging, Britain, Brunei, buying, Cambridge, Canadian, capacity, capita, carryback, catalytic, causality, CBR, certainty, channel, cheaper, Chia, cisplatin, Clin, closure, Cogent, comment, Commonwealth, compassionate, complaint, compliant, confined, contraindication, COSO, CPRA, CTTPG, cultural, culture, curative, deepened, dehydration, delisting, depleted, detect, detection, digital, discomfort, disorder, distancing, distributor, doublet, doxorubicin, ductal, dying, East, economy, edema, Eisai, elongation, emphasize, endothelial, energy, entirety, equitable, evolution, explicitly, facially, FDARA, fear, feel, fluid, fluidity, flutter, foreseen, Foster, FQHC, fullest, Garrett, gauge, GB, geography, GlaxoSmithKline, Gleevec, globe, GPDR, grace, Great, Grounded, Hanover, head, HengRui, HIV, home, honesty, Immunicum, ImmunoGen, Indian, ineligibility, infarction, Inferior, insert, inspired, insulin, Intergroup, Ireland, Irish, Jiangsu, Leahy, legitimate, lenvatinib, LF, LifeMax, lifted, liposomal, LLP, logo, London, lowest, magnitude, Malaysia, malfeasance, manmade, MAP, Med, Merck, MetaGIST, metal, metastasized, MFN, MHRA, migration, misleading, mission, mITT, Mol, monoclonal, mOS, mutationally, negligence, NJ, NOL, nonpayment, Notwithstanding, NY, obsolescence, obsolete, OECD, omitted, Oncol, onsite, osteoclast, pace, pause, paused, PBM, PDGFRB, pembrolizumab, periorbital, phosphate, placement, platinum, PLC, polymerase, Poster, precautionary, preexisting, prioritization, prioritize, prioritized, PROC, prolonged, proper, purporting, QINLOCK, ransomware, ratified, reallocated, Reauthorization, recession, regularly, reinstitute, reinstituted, remote, remotely, resale, restaging, resume, retinal, revoked, robust, save, SD, SDs, se, sequester, ship, shipping, shortage, Simon, situation, Sixteen, social, speaker, standing, steady, stewardship, Stivarga, strain, sue, sum, Sutent, Swissmedic, Switzerland, SynOx, talent, TCA, TEK, teleworking, Tesaro, text, thereof, thought, Tianqing, topotecan, transaminase, translocation, Tricare, truthful, twelve, unambiguously, uncollectible, uncovered, unemployment, unmarketability, Unum, upgrade, uptake, vasculature, vast, vimseltinib, virtual, visibility, wildtype, women, word, workforce, workplace, worse, York, Zealand

Removed: AACR, abnormal, accumulate, affiliated, affirmative, allele, allergic, Amgen, anniversary, annum, antigen, approximated, ARIAD, attributable, bargaining, black, bladder, blocker, borrowed, brain, bright, Brightstar, calculating, cancelable, Celldex, cervix, chamber, chart, CHC, checkpoint, CHMP, closing, collateralized, collective, complement, correlation, correspondingly, CRL, dated, DCR, density, destroy, destroying, diagram, direction, dissolve, divide, dramatically, driver, Eli, embezzling, enacting, eradicate, essentially, examine, examined, exhibit, explicit, expressing, fight, fighting, functioning, fundamental, gray, hematologic, hematological, heparin, histamine, immunokinase, immunosuppressed, immunosuppression, immunosuppressive, immunotolerance, inactivate, inapplicable, indispensable, indolent, infiltrate, infiltrating, infiltration, informally, interleukin, invasive, involvement, irrevocably, ISM, Jaffray, JMP, Jumpstart, KBA, leadership, lender, leukemia, leukotriene, Lilly, live, lymphocyte, macrophage, MAF, manager, MAPK, marketer, mast, master, MCL, MCSF, mediated, mice, Michael, microtubule, microvessel, midostaurin, modulated, monthly, Morgan, mouse, multiplied, murine, muscle, mutational, neoplasm, Nomura, observe, offsetting, offshore, optimal, organ, passage, PDGFR, PDMA, percent, persuade, pharmacodynamic, pharmacoeconomic, pigmentosa, Piper, Plexxikon, prevailing, prime, proliferate, proton, pump, PyMT, QSR, qualitative, quantitative, randomization, remeasured, repatriated, repay, replicate, represented, resilience, retrospectively, revised, SAB, salbutamol, saturation, sending, serotonin, shutting, signal, skin, SM, smoldering, spontaneously, Squibb, Src, stealing, store, sublease, subordinate, supportive, suppression, Syndax, syngeneic, Takeda, Taylor, threshold, timeframe, titled, transfected, Treg, tryptase, unregulated, urticaria, utility, validate, VEGFR, vehicle, white, wind

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated DCPH transcripts

DCPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.16(a)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

THIS AMENDMENT NO. 1 (“Amendment 1”) is made effective as of June 10, 2020 (“Amendment 1 Effective Date”) by and between Deciphera Pharmaceuticals, LLC with offices located at 200 Smith Street, Waltham, MA 02451 (“Company”) and Thomas P. Kelly ("Executive”).

BACKGROUND. Company and Executive have entered into and executed an Employment Agreement dated October 17, 2017 (the “Agreement”) and following a review of executive compensation by the Board of Directors of Deciphera Pharmaceuticals, Inc., the Parties desire to amend the Agreement to revise certain Change in Control benefits.

NOW THEREFORE, intending to be legally bound, the Parties agree as follows:

1.Section 5(a)(i) of the Agreement is hereby deleted and replaced in its entirety as follows: “the Company shall pay the Executive a lump sum amount equal to one-and-a-half (1.5) times the sum of (A) the Executive’s then current Base Salary plus (ii) the Executive’s Target Annual Cash Incentive Compensation for the then-current year.”

2.The reference to “12 months” of COBRA health continuation payments in Section 5(a)(ii)(i) of the Agreement shall be changed to “18 months.”

3.All capitalized terms used, but not otherwise defined, in this Amendment 1 will have the same meaning given to them in the Agreement. All references to “Agreement” in the Agreement and this Amendment 1 are deemed to include this Amendment 1.

4.Except as specifically set forth in this Amendment 1, the Agreement remains unchanged and in full force and effect.

IN WITNESS WHEREOF, each Party has caused this Amendment 1 to be executed as of the Amendment 1 Effective Date.


Deciphera Pharmaceuticals, LLC By: /s/ Steven Hoerter Name: Steven Hoerter Title: President and Chief Executive Officer			EXECUTIVE /s/ Thomas P. Kelly Name: Thomas P. Kelly